(RTTNews) - Wednesday, Blackstone Inc. (BX) announced a new partnership with Moderna, Inc. (MRNA) through a development and commercialization funding agreement, funds managed by Blackstone Life Sciences will provide up to $750 million to support Moderna's influenza program.
If successful, Blackstone Life Sciences may receive milestones and royalties from the resulting flu products.
Moderna will consider the funding as a deduction in research and development costs and will maintain complete ownership and oversight of the Company's influenza initiative.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
